Bristol Myers (BMY) recently announced that a late-stage study, seeking to expand the label of its cancer combination drug, Opdivo (nivolumab) and Yervoy (ipilimumab), failed to meet the primary endpoint of progression-free survival in unresectable, locally advanced stage III non-small cell lung cancer (NSCLC).The phase III CheckMate -73L study evaluated Opdivo with concurrent chemoradiotherapy (CCRT) followed by Opdivo plus Yervoycompared with CCRT followed by AstraZeneca’s (AZN) Imfinzi (durvalumab) in 92 ...

Bad news can be good news for an enterprising investor with a longer time horizon than the market's immediate reaction.About once every 90 days, publicly traded companies have to face their shareholders and let them know how their businesses have performed over the past quarter. Those earnings releases often bring with them all sorts of news that can move the market.Sometimes that news is bad, which can knock a company's stock down. Yet that can provide an opportunity for investors to buy shares at a bargai ...

Should investors brace for a dividend cut?Bristol Myers Squibb (BMY 0.45%) pays investors an attractive dividend, which yields an incredibly high rate of 5.5%. That's nearly four times the S&P 500 average of 1.4%. At such a high rate, investing approximately $18,200 would be enough to generate $1,000 in annual dividends from the stock.However, as is the case with many high-yielding stocks, Bristol Myers' dividend comes with some risk. The company's growth has been a concern for investors, and recently, its ...

Key PointsA dismal report from CVS has sent shares plunging, but they already look to have put in a low. Bristol-Myers is experiencing something similar, with a big day of gains yesterday boding well for next week. TripAdvisor shares are still recovering from Wednesday's shock and hold the most risk but also the most reward. 5 stocks we like better than CVS HealthSavvy stock investors often look for bargains using the Relative Strength Index (RSI). This technical tool evaluates a stock's performance over th ...

They offer plenty of upside and solid dividend growth.It's easy to find stocks that are lagging broader equities, even in a bull market like the one we're currently in. It's harder to find beaten-down stocks that still look worth buying and holding onto for a while. Some corporations are condemned to deliver subpar financial results and stock market performances practically in perpetuity.Thankfully, Bristol Myers Squibb (BMY 2.45%) and Pfizer (PFE 1.19%), two drugmakers that are failing to keep pace with br ...

Completed adult cohort enrollment and enrolled multiple patients in the adolescent cohort of the Phase 1/2/3 RUBY clinical trial of reni-cel for severe sickle cell disease On track to present additional clinical data from the RUBY trial and the EdiTHAL trial of reni-cel for transfusion-dependent beta-thalassemia in mid-2024 and additional updates by year-end 2024 Presenting pre-clinical data at ASGCT on in vivo capabilities to support development of transformative in vivo gene editing medicines Strong finan ...

文章核心观点 - Editas Medicine宣布与Bristol Myers Squibb的合作延长两年，且有再延长两年的选项，双方将继续研究、开发和商业化用于治疗癌症和自身免疫性疾病的T细胞药物 [1] 合作情况 - 合作延长至2026年，有两个一年期延长选项，可将合作关系延续到2028年 [3] - Bristol Myers Squibb已选择参与11个基因靶点的13个不同项目，其中两个项目处于IND启用研究阶段，四个项目处于后期发现阶段 [1] 合作条款 - Editas Medicine可开发基因组编辑工具，Bristol Myers Squibb有权选择使用这些工具开发基因编辑的α-β T细胞疗法 [2] - Bristol Myers Squibb为每个使用选定基因组编辑工具开发和商业化的新实验药物，向Editas Medicine支付潜在未来里程碑付款 [2] - 合作产生的产品获批后，Editas Medicine有资格获得净销售额的分级特许权使用费 [2] 过往合作 - 2015年Editas Medicine与Juno Therapeutics（现Bristol Myers Squibb）开展战略研究合作，专注于开发治疗癌症的细胞疗法 [3] - 2019年协议修订，允许Editas开发非α-β T细胞疗法，扩大Bristol Myers Squibb对基因编辑α-β T细胞的使用范围 [3] Editas Medicine公司介绍 - 作为临床阶段的基因编辑公司，专注于将CRISPR/Cas12a和CRISPR/Cas9基因组编辑系统转化为治疗严重疾病的强大产品线 [4] - 目标是发现、开发、制造和商业化变革性、持久性、精准的基因组药物 [4] - 是Broad Institute的Cas12a专利以及Broad Institute和哈佛大学的Cas9专利在人类药物方面的独家被许可方 [4]

文章核心观点 新泽西州一名联邦法官周一驳回强生和百时美施贵宝对拜登政府医保药品价格谈判的法律挑战 裁定该计划符合宪法 这是拜登政府在与药企的法律斗争中又一次胜利 削弱了制药行业策略 医保药品价格谈判是拜登法案关键政策 旨在让昂贵药物更实惠 但会影响药企利润 首轮谈判药品最终价格2026年生效 [1] 药企法律挑战情况 - 强生和百时美施贵宝在单独诉讼中称 谈判是政府对其药品的违宪没收 侵犯言论自由 且参与医保计划的谈判条件违宪 [2] - 3月 强生、百时美施贵宝、诺和诺德和诺华在新泽西向法官夸里希进行口头辩论 [3] 法官裁决情况 - 新泽西地区法官夸里希在26页意见书中称 参与价格谈判及医保市场是自愿的 谈判不要求药企为政府或医保受益人预留药品 也不强迫药企以新价格交付药品 [2] - 夸里希认为 向医保销售药品利润可能降低 但不影响药企参与的自愿性 该计划未导致对两家药企药品的实际占有或直接征用 [3] - 3月 特拉华州一名联邦法官驳回阿斯利康对谈判的单独诉讼 2月 得克萨斯州一名联邦法官驳回对价格谈判的单独诉讼 9月 俄亥俄州一名联邦法官驳回美国商会阻止价格谈判的初步禁令请求 [3] 药企回应情况 - 强生和百时美施贵宝未立即对裁决置评请求作出回应 [2]

文章核心观点 Repertoire与百时美施贵宝达成多年战略合作，利用Repertoire的DECODE平台和百时美施贵宝的专业知识，开发针对多达三种自身免疫性疾病的耐受性疫苗，为患者提供有效、选择性和持久的治疗方案 [1][2] 合作内容 - Repertoire将获得6500万美元的预付款，并有资格获得高达18亿美元的里程碑及其他付款和分级特许权使用费 [1][2] - Repertoire负责候选药物开发提名前的所有活动，百时美施贵宝将根据独家全球许可负责耐受性疫苗的临床开发、监管事务和商业化 [2] - Repertoire将利用其T细胞受体（TCR）-表位发现平台DECODE及其专有的脂质纳米颗粒递送技术，发现和开发耐受性疫苗候选药物，并在临床开发期间监测患者对耐受性疫苗的免疫反应 [2] 双方表态 - Repertoire首席执行官认为该协议认可了DECODE平台的变革性力量，合作能将DECODE的发现转化为治疗自身免疫性疾病的潜在变革性药物 [3] - 百时美施贵宝高级副总裁表示合作旨在选择性重置免疫系统，是其免疫学研究战略的关键组成部分，有望带来长期益处并减少广泛免疫抑制的意外后果 [3] Repertoire公司介绍 - 致力于基于人类T细胞库开发治疗癌症、传染病和调节自身免疫性疾病免疫功能的药物 [4] - 专有的DECODE平台能全面了解疾病中T细胞受体与其抗原之间的相互作用，可用于开发新型免疫疗法 [5] - 由Flagship Pioneering于2019年创立，团队分布在马萨诸塞州剑桥市和苏黎世 [5]

文章核心观点 - 逆势投资可能带来丰厚回报，文章介绍AT&T和Bristol - Myers Squibb两只股价表现不佳但有投资价值的股票，认为它们对进取型投资者是不错选择 [1] AT&T相关情况 - 因过去收购失败和管理失误遭投资者批评，过去一年股价表现逊于同行，下跌5%，而Verizon和T - Mobile分别上涨6%和12% [2] - 2024年第一季度业绩超盈利预期，净后付费用户增加34.9万，客户流失率0.72%为历史第一季度最低，零售后付费ARPU同比增长1%至55.57美元 [4] - 管理层预计今年EBITDA增长3%，得益于第一季度4.3%的增长、无线客户留存和光纤网络铺设，目前光纤市场渗透率达40%，过去12个月光纤客户增加110万，总数达860万 [4] - 注重资产负债表去杠杆化，第一季度净债务与EBITDA比率降至2.9倍，目标是2025年上半年降至2.5倍 [4] - 股息收益率6.7%，派息率35%，当前股价16.58美元，远期市盈率7.5倍，低于Verizon和T - Mobile [4] - 市场定价反映每股收益下降，而卖方分析师预计未来两年年均每股收益增长3.5% [4] Bristol - Myers Squibb相关情况 - 是专注心血管、肿瘤和免疫学治疗领域的大型制药公司，过去52周股价下跌37%，表现逊于SPDR Pharmaceutical ETF（XPH）的8%跌幅 [5] - 市场担忧其畅销药Revlimid面临仿制药竞争，但2024年第一季度营收同比增长5%（外汇中性基础上6%），受Eliquis、Reblozyl和Opdualag推动，部分被Opdivo和Revlimid抵消 [6] - 第一季度净亏损因一次性收购IPRD费用和许可收入影响，每股亏损6.30美元 [6] - 未来5年有强大产品线应对专利悬崖，包括治疗精神分裂症的KarXT、肺癌药物Opdualag和ADC癌症治疗药物SystImmune [6] - 资产负债表强劲，现金及等价物近100亿美元，自2022年底净债务减少27亿美元，计划未来2年再偿还100亿美元，标准普尔信用评级为A，净债务与TTM EBITDA比率1.56倍 [7] - 近期股价疲软使股息收益率达5.4%，派息率31%，过去5年股息复合年增长率7.6%，连续7年股息增长 [7] - 当前股价44.70美元，混合市盈率8.4倍，远低于历史市盈率16.7倍，预计长期每股收益年均增长5% [9] 投资建议 - 两只股票虽有风险但价格已充分反映，市场忽视其积极因素和催化剂，对逆向投资者是不错价值投资机会 [11]